Reversal of acute and chronic synovial inflammation by anti- transforming growth factor beta by unknown
Brief De~nitive Report 
Reversal of Acute and Chronic Synovial Inflammation 
by Anti-Transformlng Growth Factor 3 
By S. M. Wahl,* J. B. Allen,* G. L. Costa,* H. L. Wong,* 
and J.  R.  Dasch~ 
From the "Laboratory of Immunology, Cellular Immunology Section, National Institute of 
Dental Research, National Institutes of Health, Bethesda, Maryland 20892; and *Cehrix 
Pharmaceuticals, Inc., Santa Clara, California 95052 
Summary 
Transforming growth factor 3 (TGF-3) induces leukocyte recruitment and activation, events central 
to an inflammatory response.  In this study, we demonstrate that antagonism of TGF-3 with 
a neutralizing antibody not only blocks inflammatory cell accumulation, but also tissue pathology 
in an experimental model of chronic erosive polyarthritis. Intraarticular injection of monoclonal 
antibody 1Dll.16, which inhibits both TGF-B1 and TGF-32 bioactivity, into animals receiving 
an arthropathic dose of bacterial cell walls significantly inhibits arthritis. Inhibition was observed 
with a single injection of 50 #g antibody, and a 1-mg injection blocked acute inflammation 
>75% compared with the contralateraljoints injected with an irrelevant isotype control antibody 
(MOPC21) as quantitated by an articular index (AI  =  0.93  _+  0.23 for 1Dl1.16,  and AI  = 
4.0 _+ 0 on day 4; iv <0.001). Moreover, suppression of the acute arthritis achieved with a single 
injection of antibody was sustained into the chronic, destructive phase of the disease (on day 
18, AI =  0.93  _  0.07 vs. AI =  2.6 _+ 0.5; p <0.01). The decreased inflammatory index associated 
with anti-TGF-/~ treatment was consistent with histopathologic and radiologic evidence of a 
therapeutic response.  These data implicate TGF-3 as a profound agonist not only in the early 
events responsible for synovial inflammation, but also in the chronicity of streptococcal cell wall 
fragment-induced inflammation culminating in destructive pathology. Interrupting the cycle 
of leukocyte recruitment and activation with TGF-B antagonists may provide a mechanism for 
resolution of chronic destructive lesions. 
T 
ransforming growth factor 3  (TGF-/~) has emerged as 
an unrivaled natural inhibitor of many immune-mediated 
pathways. Not only does TGF-3 inhibit a variety of immune 
functions in vitro (reviewed in reference 1), but more recent 
evidence has documented the ability of this cytokine to re- 
verse inflammation and immune-mediated  pathology in vivo 
(1-5).  However, therapeutic efficacy has been reported only 
after  systemic administration of TGF-3, whereas localized 
injections of TGF-fl appear to precipitate a self-limiting inflam- 
matory response with accumulation of leukocytes (6-8). These 
data are consistent with in vitro evidence that TGF-3 is a 
strong chemoattractant for neutrophils, monocytes, and T 
cells (9-11).  Moreover,  TGF-3 facilitates the migration of 
monocytes into tissue by augmenting integrin expression and 
production of matrix-degrading enzymes (1). Additionally, 
TGF-~ induces Fc3,KIII expression on blood monocytes (12) 
and triggers the production of I1,1, TNF, I1,6, and TGF-3 
itself (13, 14), thereby expanding the inflammatory network. 
These observations, along with numerous demonstrations of 
active TGF-3 peptide within inflammatory lesions (1), im- 
plicate TGF-3 as an early  agonist of inflammatory events. 
However, within a particular inflammatory site, it may be 
unclear whether TGF-3 is functioning as a mediator of inflam- 
mation or in the suppression of these events. 
One approach to this question, not yet fully explored, is 
the use of TGF-/3 antagonists to establish  cause and effect 
of this potent cytokine. In this study, we have utilized a neu- 
tralizing antibody to TGF-fl and administered it locally within 
an inflammatory site in the synovium of animals receiving 
an arthropathic dose of bacterial cell walls. The group A strep- 
tococcal cell wall fragments (SCW) induce a characteristic 
pattern of acute synovitis followed by chronic mononuclear 
cell-mediated destructive lesions (2). The antibody to TGF-~, 
as compared with an irrelevant antibody, dearly suppressed 
leukocyte accumulation and the sequelae of events culminating 
in joint destruction. Thus, TGF-fl, released early in the inflam- 
matory cascade and concentrated locally, appears to be a pro- 
tagonist for those inflammatory events leading to synovitis 
and T  cell-dependent erosive joint disease. 
Materials and Methods 
Induction and Treatment of Arthritis.  Arthritis was induced in 
pathogen-free female  LEW rats  (Harlan Sprague Dawley,  Indi- 
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ments from group A streptococci (SCW) (30 #g rhamnose/g body 
weight) (2). The course of acute and chronic joint pathology was 
clinically monitored by determining the articular index (AI), which 
reflects the degree of joint erythema,  swelling, and distortion  on 
a scale of 0 (normal) to 4 (severe  inflammation) for each  joint. Radio- 
graphs taken with direct exposure (1:1) on X-Omat TL Kodak film 
using 60-kV, 345-mA, 60-s exposure were evaluated for soft tissue 
swelling, joint space narrowing,  bone erosions, and deformity. 
SCW-injected and control LEW rats were injected intraarticu- 
lady into one of the hind ankles with neutralizing mAb to TGF-fl 
(1Dl1.16) (15) in 25 #1 PBS, PBS only, or an irrelevant isotype con- 
trol mouse mydoma Ig (MOPC21, IgG1) at the indicated concen- 
trations and times relative to SCW injection. Antibodies 11311.16 
and MOPC21 contained <0.8 ng/mg endotoxin as determined by 
the limulus assay. 
Histo~thology.  At various intervals, tissue specimens were fug~cl 
in 10% buffered formalin,  decalcified in 10% EDTA, sectioned, 
and stained with hematoxylin and eosin for histopathologic  anal- 
),sis as described (2). 
RNA Isolation  and Northern Analysis.  Total RNA was isolated 
from excised synovial tissues (6), and 5 #g total RNA was frac- 
tionated on 1% gels before being transferred to nitrocellulose filters. 
The blots were prehybridized  for 4 h and then  hybridized over- 
night  with 3zP-labded cDNA probe for human  IL-lfl,  and rat 
glyceraldebyde-3-phosphate  dehydrogenase (GAPDH), as described 
(6). The blots were then exposed to phosphor screens and analyzed 
using a Phosphor-Imager  (Molecular Dynamics, Sunnyvale, CA). 
The resultant images were then printed on a Laser  Jet III (Hewlett- 
Packard Co., Palo Alto, CA) grey-scale  printer and quantitated using 
ImageQuant (Molecular Dynamics)  software. 
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Figure 1.  Inhibition  of acute and chronic arthritis by anti-TGF-fl. Animals 
were injected in one hind joint with 1 mg mAb 1Dl1.16 or MOPC21 
just before the intraperitoneal injection of an arthropathic dose of SCW 
on day 0. Articular indices (AI) were  determined at the indicated intervals 
and data represent the mean •  SE for four animals. (Inset)  Animals in- 
jected with SCW were treated with MOPC21 at 0.5 mg or with 0.05, 
0.5, or 1.0 mg anti-TGF-fl  in 25 #l PBS on day 0, and AI were determined 
during the acute (day 4) and chronic phase (day 18). Data represent the 
mean  +  SE of four animals for each dose of antibody. 
Results 
Clinically Evident Suppression of Arthritic  Lesions by Anti- 
TGF-B.  Dissemination and localization of SCW to the sy- 
novium initiates  an acute inflammatory response clinically 
detected by an elevated articular index (AI) within hours and 
maximal by 3-5 d (Fig.  1). The anti-TGF-B mAb 1Dl1.16, 
which neutralizes both TGF-fll and TGF-fl2, was administered 
locally into the synovial space just before the systemic injec- 
tion of the arthritogenic dose of SCW. In those joints receiving 
a single intraarticular  injection of 1 mg anti-TGF-fl,  the AI 
was reduced ~75% at 24 h compared with the contralateral 
joints injected with an equivalent amount of the isotype control 
antibody (Fig.  1). During the peak of the acute inflamma- 
tory responses (days 3-5),  the AI for the animals receiving 
anti-TGF-fl remained  significantly below the clinical index 
for those injected with MOPC21  (AI  =  0.93  _+  0.23 for 
1Dl1.16  vs.  4.0  +  0  for  MOPC21;  p  <0.001).  Neither 
1Dl1.16 nor MOPC21 injected into naive joints of nonar- 
thritic animals independently induced inflammation (AI  = 
0).  Suppression of arthritis  by anti-TGP-fl was localized in 
that no suppression was seen in the contralateral hind limb 
or the two front limbs in the absence of direct injection of 
antibody. 
After the nadir (days 7-12), in which the acute phase sub- 
sides and the cellular infiltrate within the synovial tissue be- 
comes predominantly mononuclear leading to joint destruc- 
tion,  the AI of the control animals treated with MOPC21 
typically increased, reaching maximal scores within 2-3 wk 
after the SCW injection (Fig.  1). In marked contrast, animals 
injected intraarticularly with but a single l-rag dose of anti- 
TGF-fl  on  day 0  exhibited  clinical  scores  that  remained 
significantly below the control levels for the duration of the 
experiment  (day 18; p  <0.005). 
To determine if lower doses of the antibody to TGF-fl could 
modulate the course of arthritis,  a single injection of 0.05-1 
mg  1Dl1.16 .was administered  coincident  with  the SCW. 
Whereas MOPC21 often exacerbated the synovitis, as shown 
in Fig. 1, inset, a significant suppression of both acute (day 
4) and chronic (day 18) inflammation was apparent at con- 
centrations  as low as 50 #g of anti-TGF-fl,  with maximal 
benefit from the single 1-mg injection. Strikingly, the single 
injection of antibody suppressed not only the SCW-induced 
inflammation responsible for soft tissue swelling (Figs. 1 and 
2 A), but also the subsequent events essential for the evolu- 
tion of chronic arthritis, as evidenced by reduced destruction 
of bone and cartilage (Fig. 2 B). Moreover, when anti-TGF-fl 
(0.5-1.0 rag, i.a.) was not administered until after the chronic 
phase of the response had begun (day 13), the antibody was 
still significantly inhibitory (AI  =  3.2  +  .45 for MOPC21 
vs.  1.0  _+  0  for  1Dl1.16,  day 18; p  <0.05). 
A nti-TGF-~ Suppresses Inflammatory Cell Recruitment, Syno- 
vitis, and Bone Resorption.  SCW localization to the synovium 
induces a characteristic pattern of leukocyte infiltration (Fig. 
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swelling, bone deformities, and histopatbol- 
ogy. Based on joint swelling (A) and radi- 
ologic  evaluation (B) at 4 wk, arthritic  joints 
t~ceiving a single intraarticular  injection of 
anti-TGF-~ (0.7 mg) on day 0 exhibited re 
duced inflammation and tissue destruction 
as compared with the contralateraljoint  in- 
jected with PBS (shown)  or MOPC  21. 
Animals receiving an arthropathic dose of 
SCW (C and D) or no SCW (E) were in- 
jected intraarticularly with TGF-/3 mAb (/3 
and E) or MOPC21 (C). Tissues were ex- 
cised and processed for histopathology  after 
4 wk. 
2 C) that is markedly inhibited in the synovium of SCW- 
injected animals receiving anti-TGF-/3 (Fig. 2 D). Whether 
evaluated at 3 d (not shown) or 4 wk (Fig. 2) after SCW- 
induced arthritis,  the synovial tissues of anti-TGF-/3-treated 
animals exhibited a significant decrease in inflammatory cells, 
more closely resembling the control synovium (Fig. 2 E) than 
the arthritic synovium (Fig.  2 C). 
Corresponding to the decrease  in synovitis, a marked reduc- 
tion in pannus, bone erosion, and cartilage degradation was 
evident. Whereas pronounced osteodast formation and bone 
resorption were observed in arthritic joints with or without 
MOPC21 (Fig. 3 A), osteodasts were seldom seen in 1D11.16- 
treated  joint tissues (Fig. 3 B). In parallel with the histopath- 
ologic evidence of reduced tissue destruction, radiologic ex- 
amination of antibody-treated and untreated joints revealed 
diminished soft tissue swelling and minimal bone abnormal- 
ities after anti-TGF-/3 administration (Fig. 2 B). Because  TGF-/3 
is not known to directly influence bone resorption, we ad- 
dressed the effects of antagonizing TGF-/3 activity on I91 
that does promote osteoclast activation. Synovial tissues from 
arthritic animals treated intraarticularly with MOPC21 (500 
/~g) or anti-TGF-/3 (0.05-1.0  mg) were excised, RNA iso- 
lated,  and probed with IL-1/3 cDNA by Northern analysis. 
A dose-dependent  decrease in I91/3 mKNA was detected in 
the synovia receiving anti-TGF-/3 as compared with the iso- 
type control antibody (Fig. 3 C). These data implicate a causal 
role for TGF-/3 in leukocyte recruitment and activation leading 
to the release of cytokines essential for SCW-induced joint 
pathology. 
Discussion 
TGF-fl has been identified in rheumatoid synovium (12, 
16, 17), local administration of TGF-/3 to arthritic synovium 
in experimental models exacerbates the pathology (18), and 
intraarticular injections  of the cytokine independently ini- 
tiate a self-limiting  synovitis  (6,  7),  all pointing to a pro- 
tagonist role for TGF-/3 in the evolution of arthritis. As more 
direct evidence, we now demonstrate that neutralizing anti- 
bodies to TGF-/3 markedly suppress both the acute and chronic 
phases of arthritis induced by SCW. How the antibody exerts 
this antiinflanamatory effect is uncertain, but the most striking 
consequence is the paucity of leukocytes in the synovium. 
Anti-TGF-/3 most likely has a primary effect in blocking leu- 
kocyte recruitment into the synovium after deposition of the 
SCW by neutralizing the potent chemotactic activity of this 
cytokine and its ability to augment adhesion. TGF-/3 is released 
after exposure of mononuclear phagocytes to SCW (19), and 
is likely present early after localization of the SCW fragments 
in the synovium. Not only is TGF-/3 chemotactic (9-11), but 
it increases monocyte expression of ot3~1 and ors/31 integrins, 
which can promote cell matrix interactions  and localization 
of these  cells at  sites of inflammation (20).  Through its 
influence  on monocyte type IV coUagenase  production, TGF-/3 
also may contribute to the extravascularization of these cells 
(20). By antagonizing these early activities of TGF-/3, the 
requisite cellular influx appears to be inhibited, compromising 
the entire inflammatory response. 
In addition to its recruitment potential, TGF-/3 elicits other 
activities of undifferentiated monocytes, including CD16 ex- 
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osteoclasts,  bone  resorption,  and 
IL-1. SCW-induced arthritic animals 
were injected  intraarticularly with 
MOPC21 (A) or anti-TGF-fl (/3) on 
day 0, and joint tissues ~ised 4 wk 
later were processed for histopath- 
ologic analysis. (C) Synovial tissues 
were  excised  from  arthritic  ani- 
mals injected 18 d previously with 
MOPC21  (0.5  mg)  or  with  in- 
creasing concentrations of anti-TGF-fl 
(0.05-1.0 rag). Total RNA was ex- 
tracted,  and  5.0-/~g aliquots  were 
subjected to Northern analysis using 
IIAfl and GAPDH cDNA probes. 
Blots were scanned, and the histo- 
gram represents  the densitometric 
ratio of the IL,  lfl to GAPDH signal. 
Data are representative  of two ex- 
periments. 
pression (12) and the induction of TNF-cz, Ibl, and II--6 (9, 
13, 14), which are important in the cytokine cascade respon- 
sible for development of an immunologic challenge.  Based 
on recent evidence that TGF-fl promotes proliferation and 
development of CD4 + T cell precursors into Th cell popu- 
lations (Thl) (21, 22),  it is not surprising that inhibition  of 
TGF-fl activity diminishes the SCW antigen-dependent  im- 
mune events. Besides the effects on lymphocyte  and mono- 
cyte phenotype  and function,  a dramatic reduction  in os- 
teoclasts was apparent in the antibody-treated  joints, but not 
in the joints receiving MOPC21.  Since TGF-fl is thought 
to stimulate osteoblast growth and bone formation (23), and 
to block osteoclast activity (24), this inhibitory effect of anti- 
TGF-fl may be indirect,  the consequence of impairing the 
antecedent inflammation  and immune response. 
Although TGF-fl identified within inflammatory lesions 
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in a suppressive capacity in immune and inflammatory events, 
one must now also consider that TGF-3 is, in fact, contributing 
to the evolution of these events.  Antagonism of TGF-3 ac- 
tivity locally interrupts, rather than enhances, the T cell-de- 
pendent  immune response  in  the  SCW-induced  arthritis 
model. 
In inflammation and repair, the role of TGF-fl may focus 
initially on recruitment and activation of immature leuko- 
cyte populations,  whereas TGF-~ may suppress  inflamma- 
tory functions in these cells after they become activated. For 
example, TGF-fl has disparate effects on immature monocytes 
and on differentiated macrophages. Whereas blood mono- 
cytes are exquisitely sensitive to recruitment and activation 
by TGF-B, once these cells undergo differentiation they ex- 
perience TGF-~ receptor downregulation with loss of sensi- 
tivity to TGF-~ stimulation (25),  and inactivation by this 
peptide (26). After subserving their functions to process and 
eliminate foreign agents or pathogens, mononuclear phago- 
cyte responsiveness to TGF-fl is reversed during cell matura- 
tion. Similarly, immature T cells are susceptible to upregula- 
tion by TGF-fl (21, 22), whereas once activated, T cells express 
increased TGF-fl receptors and are growth arrested after ligand 
binding (27).  Thus, TGF-3 is a pivotal mediator, beneficial 
both in the initiation and in the resolution of fundamental 
inflammatory processes (1). Importantly, as leukocyte sensi- 
tivity to TGF-3 stimulation wanes, the influence of this pep- 
tide on events central to tissue repair becomes apparent as 
healing occurs (1, 8, 28). However, in chronic lesions, excess 
production or lack of regulation of this otherwise normal 
growth factor may lead to excessive leukocyte recruitment 
and activation with the potential for tissue destruction and/or 
fibrosis. In circumstances where TGF-fl contributes to patho- 
genesis,  TGF-~ antagonists may be useful in breaking the 
cycle of cell recruitment and activation. 
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